BRPI0508051A - derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes - Google Patents

derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes

Info

Publication number
BRPI0508051A
BRPI0508051A BRPI0508051-7A BRPI0508051A BRPI0508051A BR PI0508051 A BRPI0508051 A BR PI0508051A BR PI0508051 A BRPI0508051 A BR PI0508051A BR PI0508051 A BRPI0508051 A BR PI0508051A
Authority
BR
Brazil
Prior art keywords
diabetes
heteroarylaminopyrazole
treatment
derivatives usable
derivatives
Prior art date
Application number
BRPI0508051-7A
Other languages
English (en)
Inventor
Joachim Rudolph
Philip Wickens
Chih-Yuan Chuang
Libing Chen
Steven Magnuson
Alan Olague
Ning Qi
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of BRPI0508051A publication Critical patent/BRPI0508051A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE HETEROARILAMINOPIRAZOL UTILIZáVEIS PARA O TRATAMENTO DE DIABETES". A presente invenção refere-se aos compostos heteroarilaminopirazol, às composições farmacêuticas, e aos métodos para tratar diabetes e distúrbios relacionados.
BRPI0508051-7A 2004-02-27 2005-02-24 derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes BRPI0508051A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54833104P 2004-02-27 2004-02-27
US57290604P 2004-05-20 2004-05-20
PCT/US2005/005794 WO2005086656A2 (en) 2004-02-27 2005-02-24 Heteroarylaminopyrazole derivatives useful for the treatment of diabetes

Publications (1)

Publication Number Publication Date
BRPI0508051A true BRPI0508051A (pt) 2007-07-17

Family

ID=34976070

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508051-7A BRPI0508051A (pt) 2004-02-27 2005-02-24 derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes

Country Status (17)

Country Link
US (2) US7517878B2 (pt)
EP (1) EP1720863A4 (pt)
JP (1) JP2007525513A (pt)
KR (1) KR20060124727A (pt)
AR (1) AR049418A1 (pt)
AU (1) AU2005220723A1 (pt)
BR (1) BRPI0508051A (pt)
CA (1) CA2557527A1 (pt)
EC (1) ECSP066883A (pt)
IL (1) IL177232A0 (pt)
MA (1) MA28479B1 (pt)
NO (1) NO20064325L (pt)
PE (1) PE20051159A1 (pt)
RU (1) RU2006134004A (pt)
TW (1) TW200538130A (pt)
UY (1) UY28774A1 (pt)
WO (1) WO2005086656A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007005857A (es) 2004-11-17 2007-10-10 Mikana Therapeutics Inc Inhibidores de cinasa.
WO2006065590A2 (en) * 2004-12-16 2006-06-22 Xtl Biopharmaceuticals Inc. Pyridine and pyrimidine antiviral compositions
WO2006105127A2 (en) 2005-03-31 2006-10-05 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
BRPI0616630B8 (pt) * 2005-09-30 2021-05-25 Miikana Therapeutics Inc compostos de pirazol substituídos
RS53981B1 (sr) 2006-03-24 2015-10-30 Array Biopharma Inc. Analozi 2-aminopiridina kao aktivatori glukokinaze
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
JP5450108B2 (ja) * 2007-03-23 2014-03-26 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤としての２−アミノピリジン類似体
JP2010529193A (ja) * 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
EA019104B1 (ru) 2007-09-21 2014-01-30 Эррей Биофарма Инк. Активаторы глюкокиназы
US9315449B2 (en) * 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
EP2135865A1 (de) 2008-06-17 2009-12-23 Bayer CropScience AG Substituierte 1-(Diazinyl) pyrazol-4-yl-essigsäuren, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
EP2194052A1 (de) 2008-12-06 2010-06-09 Bayer CropScience AG Substituierte 1-(Thiazolyl)- und 1-(Isothiazolyl)pyrazol-4-yl-essigsäuren, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PL2485731T4 (pl) * 2009-10-06 2017-07-31 Millennium Pharmaceuticals, Inc. Związki heterocykliczne użyteczne jako inhibitory PDK1
WO2011073098A1 (de) 2009-12-15 2011-06-23 Bayer Cropscience Ag 1-(heteroaryl)-pyrazol-4-yl-essigsäuren, verfahren zu deren herstellung und deren verwendung als herbizide und pflanzenwachstumsregulatoren
US20170291890A1 (en) * 2014-09-17 2017-10-12 Epizyme, Inc. Heterocycle substituted amino-pyridine compounds and methods of use thereof
WO2016092559A1 (en) * 2014-12-12 2016-06-16 Oat & Iil India Laboratories Private Limited Substituted pyrazole derivatives having activity as fungicides
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
KR101725292B1 (ko) * 2016-03-30 2017-04-10 한국과학기술연구원 항암 활성을 갖는 신규 피리미딘-4-카르복시산 유도체
PT3472153T (pt) 2016-06-16 2021-12-31 Denali Therapeutics Inc Pirimidin-2-ilamino-1h-pirazóis como inibidores de lrrk2 para uso no tratamento de distúrbios neurodegenerativos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405207A1 (de) * 1994-02-18 1995-08-24 Bayer Ag N-Pyrazolylaniline und N-Pyrazolylaminopyridine
US20020103185A1 (en) * 2000-08-31 2002-08-01 Sanner Mark A. Pyrazole derivatives
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7319102B1 (en) * 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors

Also Published As

Publication number Publication date
MA28479B1 (fr) 2007-03-01
WO2005086656A2 (en) 2005-09-22
JP2007525513A (ja) 2007-09-06
WO2005086656A3 (en) 2005-12-29
KR20060124727A (ko) 2006-12-05
PE20051159A1 (es) 2006-02-22
TW200538130A (en) 2005-12-01
IL177232A0 (en) 2006-12-10
CA2557527A1 (en) 2005-09-22
AU2005220723A1 (en) 2005-09-22
ECSP066883A (es) 2006-11-24
NO20064325L (no) 2006-11-22
US20050192294A1 (en) 2005-09-01
US20090209451A1 (en) 2009-08-20
US7517878B2 (en) 2009-04-14
EP1720863A4 (en) 2009-04-22
EP1720863A2 (en) 2006-11-15
AR049418A1 (es) 2006-08-02
RU2006134004A (ru) 2008-04-10
UY28774A1 (es) 2005-08-31

Similar Documents

Publication Publication Date Title
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
DK2150530T3 (da) Substituerede sulfonamid-derivater
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
EA200900023A1 (ru) Применение замещенных 2-аминотетралинов для изготовления лекарственного средства для предупреждения, облегчения и/или лечения разных видов боли
BRPI0619153A8 (pt) derivados de 4-aminopirroltriazina substituída, e composição farmacêutica
SE0301010D0 (sv) Novel compounds
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
SE0301009D0 (sv) Novel compounds
MX2009003981A (es) Agentes moduladores del receptor de calcio.
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren
DE602004020337D1 (de) Anticholinergika enthaltende Arzneimittel zur Behandlung von Krankheiten der ableitenden Harnwege
BR0317445A (pt) Composto, composição farmacêutica, método para o tratamento de doenças, e, uso de um composto
ATE473737T1 (de) Verwendung von 2,3-dehydronaringenin-derivaten zur behandlung von entzündungsprozessen und diese derivate enthaltende pharmazeutische zusammensetzung
DE602007013467D1 (de) 4,5,6,7-tetrahydrothienoä3,2-cüpyridinderivate als h3-modulatoren
DE602006017855D1 (de) Verwendung von n-(dibenz (b,f)oxepin-10-ylmethyl)-n-methyl-n-prop-2-inylamin (omigapil) zur prophylaxe und/oder behandlung von muskeldystrophie

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.